

KEY OPINION LEADERS

Q&A

03

Professor Jens Juul Holst is professor at the Department of Biomedical Sciences, University of Copenhagen, and at the same time affiliated with the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen



Professor Britta Siegmund is Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charité – Universitätsmedizin Berlin.



Cancer risk?

Q: How do you evaluate the threat that rectal insulin therapy might lead to colorectal cancer in patients with ulcerative colitis?

Professor Jens Juul Holst:

A: The risk is low. In fact, the risk of cancer with insulin is an old controversy, but Insulin was actually fully acquitted in the “origin” trials (NEJM 2012).

Enterocalm market penetration?

Q: Assuming that Enterocalm is safe and efficient, can Enterocalm get a place in the treatment of ulcerative colitis given the many competing treatments already available?

Professors Britta Siegmund

A: Especially in Europe, topical treatment of distal (left-sided) disease is common and well tolerated by the patients. In addition, there is a group of patients with only rectal involvement (proctitis) where the current treatment options often are inadequate. Thus, proctitis might in addition constitute a niche specific for Enterocalm.



MD. Ph.D. Johan Burisch is with the Gastro Unit, Medical Division, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark.

Johan Burisch is an established expert within the area of occurrence, disease course and prognosis of inflammatory bowel disease. He obtained the UEG Rising Star Award in 2019.

Enterocalm market penetration?

Q: What gap can Enterocalm, assuming that it is safe and efficient, in your opinion fill in the current treatment armamentarium for ulcerative colitis?

Doctor Johan Burisch

A: Most patients with ulcerative colitis will have a mild or moderate disease course, but many experience lack of efficiency of aminosalicylates. For this group, the current treatment options are limited.